Search results
Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnoea in Heart Failure
Author(s):
Sitaramesh Emani
,
William T Abraham
Added:
3 years ago
Article
Author(s):
Roland Wensel
,
Michael Arzt
,
Sylvia Montalvan-Dobmayr
,
et al
Added:
3 years ago
Periodic Breathing - Central Sleep Apnoea (CSA)
CSA is a periodic waxing and waning of ventilation. In chronic heart failure (CHF), CSA is a result of increased chemoreflex sensitivity, prolonged circulation time (low cardiac output) and low functional residual capacity (Francis et al. Circulation 2000).
In CHF, CSA is associated with advanced disease and poor prognosis (Lafranchi et al…
View more
Author(s):
Philip Adamson
Added:
3 years ago
A growing appreciation of the prevalence of sleep breathing disorders, especially as co-morbidities of disease syndromes such as chronic heart failure, has increased interest in screening, diagnosis and treatment of obstructive and central sleep apnoea. Sleep apnoea diagnosis currently requires an overnight polysomnograhic evaluation in which the disease is defined as the number of times per hour…
View more
William T Abraham
Research Area(s) / Expertise:
Job title: Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine
Author
A Review of Sleep Apnoea and its Treatment in Cardiovascular Disease - An important Intervention in…
Author(s):
Holger Woehrle
,
Jochen Müller-Ehmsen
,
Erland Erdmann
Added:
3 years ago
Article
Sleep-disordered Breathing and Heart Failure - Insights from Speckle Tracking Echocardiography
Author(s):
Masaaki Takeuchi
,
Nobuhiko Haruki
,
Yutaka Otsuji
Added:
3 years ago
Article
Author(s):
Simon G Pearse
,
Martin R Cowie
,
Rakesh Sharma
,
et al
Added:
3 years ago
Despite advances in therapy, heart failure (HF) continues to be a leading cause of hospitalisation in those over 65.1 Around 2 % of people in Europe live with HF and as many as 10 % of those over 75 years are affected.2 Prognosis continues to be poor, with approximately half of patients dying within 5 years of first hospitalisation,3 a more severe prognosis than many malignancies.4
Sleep…
View more
Author(s):
Jack Wei Chieh Tan
,
Leong Chai Leow
,
Serene Wong
,
et al
Added:
1 year ago
Author(s):
Yukiko Isekame
,
Sabiha Gati
,
Jose Antonio Aragon-Martin
,
et al
Added:
3 years ago
Marfan syndrome (MFS) is a disease in which connective tissue becomes weak secondary to fibrillin-1 mutations, resulting in aortic dilatation, aneurysm formation, aortic dissection, aortic regurgitation and mitral valve prolapse (MVP; see Table 1).
Epidemiology
MFS is an autosomal dominant condition: 75 % of all patients inherit the condition from one affected parent and 25 % are affected as…
View more
Author(s):
Douglas Bradley
Added:
1 year ago
ESC 22 - In this short interview filmed onsite at ESC Congress 2022, Dr Douglas Bradley (University of Toronto, Toronto, CA) discusses the findings of the ADVENT-HF Trial (NCT01128816).
ADVENT-HF was designed to determine if a respiratory device, Adaptive Servo Ventilation can reduce the risk of cardiovascular hospitalisations and death in patients with heart failure and sleep apnoea. 732…
View more